Follow-up of Multinodular Goiter with TIRADS 3 Nodules
For a patient with multinodular goiter containing TIRADS 3 nodules, benign cytology, normal thyroid function, and no compressive symptoms, perform the first follow-up ultrasound at 1–2 years, then repeat every 2–4 years if the nodules remain stable. 1
Initial Management Framework
TIRADS 3 nodules with benign cytology (Bethesda II) require only ultrasound surveillance—repeat fine-needle aspiration is not indicated unless suspicious changes develop. 1, 2
The malignancy risk in nodules with initial benign cytology is extremely low at 1–3%, which does not justify routine re-biopsy. 1, 2
In the context of multinodular goiter specifically, nodules without suspicious ultrasound features can be safely followed with imaging rather than repeated biopsy. 3
Recommended Surveillance Schedule
Standard Follow-up Protocol
First ultrasound: 1–2 years after initial benign diagnosis 1, 2
Subsequent ultrasounds: Every 2–4 years if nodules remain stable 1, 2
Recent evidence suggests the initial reassessment may be safely delayed to 3 years in stable, low-risk nodules. 1
When to Consider Stopping Surveillance
- In elderly patients with non-suspicious nodular disease, discontinuation of routine monitoring may be appropriate because the clinical benefit is minimal relative to competing health priorities. 2
Indications for Repeat Fine-Needle Aspiration
Repeat biopsy is warranted only in the following specific circumstances:
Growth Criteria
Significant volume increase >50% or a ≥20% increase in two nodule dimensions, particularly in solid nodules >2 cm 2
Over 5 years, only 11–29% of benign nodules demonstrate growth (average 5.9 mm increase), while 13–18% spontaneously shrink. 1, 2
New Suspicious Ultrasound Features
What Does NOT Require Repeat Biopsy
Size Alone Is Insufficient
Large nodules (>4 cm) with benign cytology and low-risk ultrasound features have a malignancy rate <1.5%. 2
Do not repeat FNA based solely on nodule size in the absence of suspicious ultrasound changes. 2, 4
Cystic Changes
- Predominantly cystic nodules that enlarge through cystic expansion do not need repeat biopsy. 2
Stable Low-Risk Features
- TIRADS 3 nodules with stable benign cytology do not require repeat biopsy regardless of follow-up duration. 2, 4
Monitoring for New Nodules
New thyroid nodules develop in 9–14% of patients during 5–10 years of follow-up, supporting the need for continued periodic ultrasound even after the index nodule is stable. 1, 2
However, fewer than 5% of new nodules are classified as high-risk, and only 3–7% meet criteria for cytological assessment. 5
Growth Risk Factors to Consider
Factors associated with higher likelihood of nodule growth include:
These factors do not change the surveillance schedule but may inform clinical discussions about prognosis.
Special Consideration for Large Nodules
Asymptomatic nodules >4 cm that are newly identified should undergo closer initial surveillance (potentially at shorter intervals) to define growth trajectory and determine whether surgical or ablative intervention becomes necessary. 1, 2
This closer monitoring is primarily to assess for development of compressive symptoms rather than malignancy risk.
Critical Pitfalls to Avoid
Do not perform annual biopsies of stable nodules with benign cytology—this constitutes overutilization without improving patient outcomes. 1, 2
Do not rely on nodule size alone to trigger repeat FNA—always integrate ultrasound risk features into decision-making. 2, 4
Do not assume all nodule growth signifies malignancy—consider nodule composition (solid vs. cystic), initial size, and ultrasound characteristics before recommending biopsy. 2
In multinodular goiter, the presence of multiple nodules does not increase individual nodule malignancy risk when ultrasound features are benign. 3